Verona Pharma (VRNA) PT Raised to $34 at BTIG - streetinsider.com

Apr 23, 2024 · BTIG analyst Thomas Shrader raised the price target on Verona Pharma (NASDAQ: VRNA) to $34.00 (from $31.00) while maintaining a Buy rating.The analyst …

$34
OFF

Verona Pharma (VRNA) PT Raised To $34 At BTIG - Streetinsider.com

2 weeks from now

Apr 23, 2024 · BTIG analyst Thomas Shrader raised the price target on Verona Pharma (NASDAQ: VRNA) to $34.00 (from $31.00) while maintaining a Buy rating.The analyst …

streetinsider.com

$34
OFF

Analyst Ratings For Verona Pharma (VRNA) - Streetinsider.com

2 weeks from now

UPDATE: Verona Pharma (VRNA) PT Raised to $34 at SunTrust BTIG Starts Verona Pharma (VRNA) at Buy SunTrust Robinson Humphrey Assumes Verona Pharma (VRNA) at Buy

streetinsider.com

$77
OFF

Verona Pharma Price Target Raised To $77 From $51 At BTIG

2 weeks from now

Jan 8, 2025 · BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 pre-announcement was "impressive", …

nasdaq.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG - Investing.com

2 weeks from now

Jan 7, 2025 · In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations …

investing.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG

2 weeks from now

Jan 7, 2025 · In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations …

investing.com

$17.00
OFF

BTIG Maintains Buy Rating For Verona Pharma: Here's What You …

2 weeks from now

Dec 20, 2022 · BTIG has decided to maintain its Buy rating of Verona Pharma (NASDAQ:VRNA) and raise its price target from $17.00 to $26.00. Shares of Verona Phar...

businessinsider.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG - Investing.com …

2 weeks from now

In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations and a …

investing.com

$44.00
OFF

Verona Pharma (NASDAQ:VRNA) PT Raised To $44.00 - MarketBeat

2 weeks from now

Oct 9, 2024 · Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verona Pharma presently has a consensus rating of Buy and an average …

marketbeat.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG - Investing.com

2 weeks from now

Jan 7, 2025 · Verona Pharma stock target raised to $77 at BTIG. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing …

investing.com

$50.57
OFF

Verona Pharma (VRNA) Stock Forecast And Price Target 2025

2 weeks from now

5 days ago · According to the 8 analysts' twelve-month price targets for Verona Pharma, the average price target is $50.57. The highest price target for VRNA is $74.00, while the lowest …

marketbeat.com

$57
OFF

Verona Pharma Price Target Raised To $57 From $44 At Truist

2 weeks from now

Jan 8, 2025 · Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the company’s positive Q4 revenue pre …

businessinsider.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG

2 weeks from now

Jan 7, 2025 · In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations …

investing.com

$31
OFF

BTIG Maintains Buy On Verona Pharma, Raises Price Target To $31

2 weeks from now

BTIG Maintains Buy on Verona Pharma, Raises Price Target to $31. Benzinga · 03/20/2023 13:44. BTIG analyst Thomas Shrader maintains Verona Pharma (NASDAQ:VRNA) with a Buy …

webull.com

$74
OFF

Verona Pharma Price Target Raised To $74 From $64 At Wells Fargo

2 weeks from now

Jan 8, 2025 · Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the shares. The firm notes …

businessinsider.com

$57
OFF

Verona Pharma (VRNA) PT Raised To $57 At Truist Securities As …

2 weeks from now

Jan 8, 2025 · Truist Securities analyst Joon Lee raised the price target on Verona Pharma (NASDAQ: VRNA) to $57.00 (from $44.00) while maintaining a Buy rating.The analyst said: …

streetinsider.com

FAQs about Verona Pharma (VRNA) PT Raised to $34 at BTIG - streetinsider.com Coupon?

What is the price target for Verona Pharma (vRNA)?

The highest price target for VRNA is $74.00, while the lowest price target for VRNA is $33.00. The average price target represents a forecasted upside of 14.23% from the current price of $44.27. Enter your email address to receive the latest news and analysts' ratings for Verona Pharma and its competitors. ...

Should you buy Verona Pharma (vRNA)?

Analysts like Verona Pharma more than other "medical" companies. The consensus rating for Verona Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VRNA compares to other companies. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. ...

Is Verona Pharma a good stock to buy?

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verona Pharma with a $43.86 average price target, which is a 14.97% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $45.00 price target. ...

When did Verona Pharma IPO?

Verona Pharma (VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. ...

What was Verona Pharma's stock price on January 1st 2024?

Verona Pharma's stock was trading at $19.88 on January 1st, 2024. Since then, VRNA shares have increased by 114.7% and is now trading at $42.68. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) issued its earnings results on Monday, November, 4th. ...

Who is Verona Pharma plc?

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. ...